Harbour Trust & Investment Management Co Purchases 22,195 Shares of Novo Nordisk A/S (NYSE:NVO)

Harbour Trust & Investment Management Co increased its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 26.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 107,261 shares of the company's stock after buying an additional 22,195 shares during the quarter. Harbour Trust & Investment Management Co's holdings in Novo Nordisk A/S were worth $7,448,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in NVO. Victory Capital Management Inc. lifted its holdings in Novo Nordisk A/S by 58.5% during the 4th quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock valued at $5,410,000 after purchasing an additional 23,223 shares during the last quarter. North Star Investment Management Corp. lifted its holdings in Novo Nordisk A/S by 18.2% during the 1st quarter. North Star Investment Management Corp. now owns 20,742 shares of the company's stock valued at $1,440,000 after purchasing an additional 3,200 shares during the last quarter. Stanley Laman Group Ltd. acquired a new stake in Novo Nordisk A/S during the 1st quarter valued at $390,000. Dover Advisors LLC acquired a new stake in Novo Nordisk A/S during the 1st quarter valued at $505,000. Finally, Natural Investments LLC acquired a new stake in Novo Nordisk A/S during the 4th quarter valued at $1,345,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Stock Performance

NYSE:NVO traded down $0.68 during trading on Thursday, reaching $69.14. The company's stock had a trading volume of 3,318,467 shares, compared to its average volume of 7,245,252. The firm has a market cap of $308.70 billion, a price-to-earnings ratio of 20.45, a price-to-earnings-growth ratio of 1.24 and a beta of 0.64. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74. The firm has a 50 day moving average of $69.69 and a 200-day moving average of $76.46. Novo Nordisk A/S has a 12 month low of $57.00 and a 12 month high of $143.69.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.92. The firm had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. Research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on NVO shares. Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. BNP Paribas started coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They set an "underperform" rating for the company. Wall Street Zen raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Saturday, June 14th. Finally, BMO Capital Markets reissued a "market perform" rating and set a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $112.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.